In the present study, we found that midostaurin, a clinically available therapeutic agent against FLT3-mutated AML and KIT-mutated systemic mastocytosis, may be repositioned to an enhancer for anti-PD-1 against colon cancer. The gene discussed is PDCD1; the disease is acute myeloid leukemia.